RECORDATI SIGNS AN EXCLUSIVE LICENSE AGREEMENT WITH THE MEYER HOSPITAL IN FLORENCE
(Thomson Reuters ONE) -
Milan, 27 February 2017 - Recordati announced the signing of an exclusive
worldwide licensing agreement covering the know-how developed by the Meyer
Hospital in Florence (Italy) for the development of a treatment for pre-term
babies affected by retinopathy of prematurity (ROP). The treatment is currently
being investigated in a phase II clinical trial by the Meyer Hospital, while
Recordati will complete the clinical development and the regulatory steps
necessary to obtain the marketing approval for the drug. Furthermore, within the
deal, Recordati shall support other Meyer projects in the rare disease area over
a period of three years based on a mutually agreed plan. This represents a
collaboration between public and private institutions which recognizes the
important results obtained by the internal research conducted by the pediatric
hospital in Florence.
Retinopathy of prematurity (ROP) is a potentially blinding eye disorder that
primarily affects premature infants weighing about 1.25 kg or less that are born
before 31 weeks of gestation (a full-term pregnancy has a gestation of 38-42
weeks). The smaller a baby is at birth, the more likely that baby is to develop
ROP. This disorder-which usually develops in both eyes-is a rare condition,
however presenting as one of the most common causes of visual loss in childhood
that can lead to lifelong vision impairment and blindness.
"We are very pleased to have entered into a long-term partnership with the
renowned Meyer Hospital in Florence" declared Andrea Recordati, Vice-Chairman
and CEO. "The ROP project represents an excellent opportunity for Recordati's
orphan drug division to strengthen its presence in neonatology worldwide, offer
a new and innovative treatment for a severe and debilitating disease and obtain
access to potentially innovative early stage opportunities".
Recordati, established in 1926, is an international pharmaceutical group, listed
on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT
0003828271), with a total staff of around 4,000, dedicated to the research,
development, manufacturing and marketing of pharmaceuticals. Headquartered in
Milan, Italy, Recordati has operations in the main European countries, in
Russia, in other Central and Eastern European countries, in Turkey, in North
Africa, in the United States of America and in some Latin American countries.
An efficient field force of medical representatives promotes a wide range of
innovative pharmaceuticals, both proprietary and under license, in a number of
therapeutic areas including a specialized business dedicated to treatments for
rare diseases. Recordati is a partner of choice for new product licenses for its
territories. Recordati is committed to the research and development of new
specialties within the urogenital therapeutic area and of treatments for rare
diseases. Consolidated revenue for 2015 was ? 1,047.7 million, operating income
was ? 278.5 million and net income was ? 198.8 million.
For further information:
Recordati website: www.recordati.com
Investor Relations Media
Relations
Marianne Tatschke
Studio Noris Morano
(39)0248787393
(39)0276004736, (39)0276004745
e-mail: inver(at)recordati.it e-mail:
norismorano(at)studionorismorano.com
Statements contained in this release, other than historical facts, are "forward-
looking statements" (as such term is defined in the Private Securities
Litigation Reform Act of 1995). These statements are based on currently
available information, on current best estimates, and on assumptions believed to
be reasonable. This information, these estimates and assumptions may prove to be
incomplete or erroneous, and involve numerous risks and uncertainties, beyond
the Company's control. Hence, actual results may differ materially from those
expressed or implied by such forward-looking statements. All mentions and
descriptions of Recordati products are intended solely as information on the
general nature of the company's activities and are not intended to indicate the
advisability of administering any product in any particular instance.
ProROP eng:
http://hugin.info/143644/R/2082150/784558.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: RECORDATI via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 27.02.2017 - 09:01 Uhr
Sprache: Deutsch
News-ID 526704
Anzahl Zeichen: 5372
contact information:
Town:
MILANO
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 139 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"RECORDATI SIGNS AN EXCLUSIVE LICENSE AGREEMENT WITH THE MEYER HOSPITAL IN FLORENCE"
steht unter der journalistisch-redaktionellen Verantwortung von
RECORDATI (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
